156 related articles for article (PubMed ID: 15641479)
1. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.
Langer CJ; Li Y; Jennings T; DeConti RC; Nair S; Cohen RB; Forastiere AA;
Cancer Invest; 2004; 22(6):823-31. PubMed ID: 15641479
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
4. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
Thödtmann F; Theiss F; Kemmerich M; Heinrich B; Laubenbacher C; Quasthoff S; Kau R; Herzog M; Diergarten K; Hanauske AR
Ann Oncol; 1998 Mar; 9(3):335-7. PubMed ID: 9602270
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
Clark JI; Hofmeister C; Choudhury A; Matz G; Collins S; Bastian R; Melian E; Emami B; Petruzzelli G
Cancer; 2001 Nov; 92(9):2334-40. PubMed ID: 11745288
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Specht L; Larsen SK; Hansen HS
Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
[TBL] [Abstract][Full Text] [Related]
9. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
10. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer.
Basaran M; Bavbek SE; Güllü I; Demirelli F; Sakar B; Tenekeci N; Altun M; Yalçin S; Onat H
J Chemother; 2002 Apr; 14(2):207-13. PubMed ID: 12017379
[TBL] [Abstract][Full Text] [Related]
13. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Stathopoulos G; Nicolaides C; Kalogera-Fountzila A; Kalofonos H; Nikolaou A; Bacoyiannis C; Samantas E; Papadimitriou C; Kosmidis P; Daniilidis J; Pavlidis N
Ann Oncol; 1999 Apr; 10(4):475-8. PubMed ID: 10370793
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
Wang TF; Chu SC; Kao RH; Yao CY; Li CC
Jpn J Clin Oncol; 2008 Jul; 38(7):459-63. PubMed ID: 18586668
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
[TBL] [Abstract][Full Text] [Related]
18. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
